ESSA Pharma Inc. (NASDAQ:EPIX) COO Peter Virsik Sells 2,082 Shares

ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) COO Peter Virsik sold 2,082 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $6.03, for a total transaction of $12,554.46. Following the sale, the chief operating officer now directly owns 9,164 shares of the company’s stock, valued at approximately $55,258.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

ESSA Pharma Trading Up 6.1 %

NASDAQ EPIX traded up $0.34 during trading on Tuesday, hitting $5.93. 979,381 shares of the company’s stock were exchanged, compared to its average volume of 93,386. The company has a market cap of $263.07 million, a PE ratio of -9.41 and a beta of 1.82. ESSA Pharma Inc. has a fifty-two week low of $2.58 and a fifty-two week high of $11.67. The stock’s 50 day moving average price is $5.12 and its two-hundred day moving average price is $6.49.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last issued its earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.10. Analysts forecast that ESSA Pharma Inc. will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in EPIX. EntryPoint Capital LLC acquired a new position in shares of ESSA Pharma in the first quarter valued at approximately $38,000. BNP Paribas Financial Markets increased its stake in shares of ESSA Pharma by 164.9% in the fourth quarter. BNP Paribas Financial Markets now owns 57,466 shares of the company’s stock valued at $379,000 after buying an additional 35,771 shares during the period. Janus Henderson Group PLC increased its stake in shares of ESSA Pharma by 7.9% in the first quarter. Janus Henderson Group PLC now owns 1,175,242 shares of the company’s stock valued at $9,978,000 after buying an additional 85,760 shares during the period. Finally, RTW Investments LP acquired a new position in shares of ESSA Pharma in the fourth quarter valued at approximately $15,171,000. Institutional investors and hedge funds own 75.12% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $17.00 price objective on shares of ESSA Pharma in a research report on Thursday, May 16th.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.